Date: 2016-03-21
Type of information: Collaboration agreement
Compound:
Company: Novasep (France) GTP Technology (France)
Therapeutic area: Technology - Services
Type agreement: collaboration
Action mechanism:
Disease:
Details: * On March 21, 2016, Novasep, a supplier of services and technologies for the life sciences industry, and GTP (Gene-to-Proteins) Technology, a CDMO providing recombinant protein and process development services, announce a partnership that combines their expertise in monoclonal antibodies (mAbs) production. The partners aim to facilitate the development of therapeutic and diagnostic candidates for European biopharmaceutical clients. GTP brings its know-how in producing mAbs at the proof-of-concept /discovery and early clinical stages. Novasep provides expertise and plant facilities for late stage production. The mid-size capacity and full range of services the partners offer fit closely with customer demand regarding expertise and fast-track process development. The partnership particularly targets mAb production for orphan drugs, ADCs and diagnostics. GTP has long-standing experience developing production processes and operates non-GMP bioreactors up to a 50L scale. This complements Novasep’s capacity of 50L, 200L and 1,000L for cGMP production, ideal for 1-10kg per year production scales.
Financial terms:
Latest news:
